[ad_1]
The US pharmaceutical company Biogen and its Japanese partner Isai have completed two end-stage adocanumab trials for the treatment of Alzheimer's disease, after efforts to seek effective treatment for the disease have been reversed. , resulting in the loss of more than $ 18 billion.
One of the latest experiments on the hypothesis that the elimination of amyloid sticky deposits from the patient's brain in the early stages of the disease could put an end to the deterioration of the disease, including memory loss and memory loss. self-care, confirmed the experts.
Peugeot shares fell by nearly 30% after the decision and posted a drop of 225.70 USD, the largest decline since February 2005.
The decision to discontinue the tests came after an independent monitoring body stated that there was more hope in the success of the tests based on the ## 147 ## # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # 39, analysis of property data.
In July, Essay announced promising results for another drug for the treatment of Alzheimer's disease, PEN 2401, developed in cooperation with Beogen, but attempts at the invention of treatment failed after a analysis of a year.
Any effective treatment for Alzheimer's disease, which affects an estimated 5.7 million Americans, will surely become one of the best-selling drugs in the world. But efforts to date have not paid off, with more than 100 experimental drugs failing.
Trials were in the late stages of the Adocanumab test in patients with mild cognitive impairment or mild dementia. The detailed results will be presented at an upcoming medical meeting.
"This disappointing news underscores the extremely difficult treatment of Alzheimer's disease and the need to further enhance neuroscience," said Michael Fontainesus, CEO of Biogen.
Biogen and Essay said they would continue to work on other treatments for the disease, including PEN 2401.
[ad_2]
Source link
